Previous close | 0.0300 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 12.50 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 63 |
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
OSAKA, Japan, May 09, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER, in a year of significant loss-of-exclusivity impact.
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments